Published by Global Banking & Finance Review®
Posted on March 2, 2026
2 min readLast updated: April 2, 2026
Add as preferred source on Google
UK biotech Oxford Nanopore Technologies saw its shares tumble nearly 12% to 117.4 pence on Monday, March 2, after the firm lowered its medium‑term revenue growth targets.
March 2 (Reuters) - Oxford Nanopore Technologies shares fell nearly 13% on Monday after the British biotech firm lowered its medium-term revenue growth target due to U.S. National Institute of Health budget constraints and challenges in the China market.
The firm said it now expects its fiscal 2027 revenue to grow broadly between 21% and 25% on a constant currency basis, down from the more than 30% it had forecast until 2027.
Analysts at Berenberg said the cut to medium-term revenue growth target has prompted them to lower their estimates.
"We can... still see a path to Oxford Nanopore growing well above our revised forecasts in the medium-term should conditions in China improve, US National Institutes of Health budget constraints reduce," Berenberg analyst Sam England said in a note.
Shares in Oxford Nanopore, which said its 2026 revenue growth will also be between 21% and 25%, were down 12.8% at 116 pence, as of 0904 GMT.
The firm reported fiscal 2025 adjusted core loss of 86.7 million pounds ($115.58 million), smaller than the prior year's loss of 117.9 million pounds on a 24.2% jump in revenue on a constant currency basis.
($1 = 0.7501 pounds)
(Reporting by Prerna Bedi in Bengaluru; Editing by Subhranshu Sahu)
Oxford Nanopore shares dropped after the company lowered its medium-term revenue growth target.
Following the decline, Oxford Nanopore shares were trading at 117.4 pence.
The announcement was reported on March 2.
Oxford Nanopore shares fell by approximately 11.6%.
Explore more articles in the Finance category
